מתוך medicontext.co.il
WESTPORT, CT (Reuters Health) – Statin therapy can substantially reduce the increased cardiac event risk found in patients with arterial inflammation who undergo coronary stenting, according to a report published in the December issue of the Journal of the American College of Cardiology.
Dr. Andreas M. Zeiher and colleagues from the University of Frankfurt in Germany assessed the outcomes of 388 patients who underwent coronary stent implantation. The group included 249 patients who received statin therapy and 139 patients who did not. In terms of arterial inflammation, 207 patients had C-reactive protein (CRP) levels of 0.6 mg/dL or higher (elevated) and 181 patients had lower levels.
Patients with elevated CRP levels who did not receive statin therapy were 2.37 times more likely to experience a major adverse cardiac event than statin-treated patients with lower CRP levels, the authors note. Among patients with elevated CRP levels, those treated with statins were about half as likely as untreated patients to experience a major event.
"Preprocedural activation of inflammatory cells appears to profoundly modify the vessel wall response to injury, leading to a significant increase in clinical complications and restenosis rates following coronary stent implantation," the investigators note. The current findings suggest that statin therapy interferes with the detrimental inflammatory effect.
Measurement of CRP levels may be a useful way of determining which patients will benefit most from statin therapy during coronary stenting, the researchers conclude.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!